Boehringer Ingelheim Schweiz

Industry / private company


Location: Basel, Switzerland (CH) CH

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial (2021) Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Journal article Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function (2020) Wuyts WA, Azuma A, Distler J, Sondergaard K, Proudman S, Cottin V, Erhardt E, et al. Conference contribution Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019) Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al. Conference contribution Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease (2019) Wollin L, Distler J, Denton CP, Gahlemann M Journal article, Review article